Publication date: Jun 10, 2026
The most common adverse events included headache, diarrhea, and cough, which occurred in 1% in the Xocova group and at a greater frequency than in the placebo group. This article has been reviewed according to Science X’s editorial process and policies . “The PEP strategy has the potential to benefit anyone who does not want to get COVID-19. All rights reserved.
| Concepts | Keywords |
|---|---|
| Coronavirus | Approval |
| Fda | Approved |
| Food | Covid |
| Headache | Day |
| Virginia | Fda |
| Included | |
| Mg | |
| Oral | |
| Pep | |
| Placebo | |
| Postexposure | |
| Prophylaxis | |
| Trial | |
| Xocova |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | cough |
| disease | MESH | diarrhea |
| disease | MESH | headache |
| disease | MESH | COVID-19 |
| disease | MESH | included |
(Visited 7 times, 1 visits today)